Thermo Fisher Scientific Inc (TMO) Stake Raised by EULAV Asset Management

EULAV Asset Management raised its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 2.6% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 39,300 shares of the medical research company’s stock after buying an additional 1,000 shares during the period. EULAV Asset Management’s holdings in Thermo Fisher Scientific were worth $6,036,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Newman Dignan & Sheerar Inc. boosted its position in shares of Thermo Fisher Scientific by 2.2% in the first quarter. Newman Dignan & Sheerar Inc. now owns 3,688 shares of the medical research company’s stock valued at $566,000 after buying an additional 80 shares during the last quarter. Quadrant Capital Group LLC boosted its position in shares of Thermo Fisher Scientific by 3.7% in the first quarter. Quadrant Capital Group LLC now owns 2,913 shares of the medical research company’s stock valued at $439,000 after buying an additional 104 shares during the last quarter. Gulf International Bank UK Ltd boosted its position in shares of Thermo Fisher Scientific by 2.1% in the first quarter. Gulf International Bank UK Ltd now owns 122,961 shares of the medical research company’s stock valued at $18,886,000 after buying an additional 2,500 shares during the last quarter. Cornerstone Investment Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $45,709,000. Finally, Catawba Capital Management VA boosted its position in shares of Thermo Fisher Scientific by 18.1% in the first quarter. Catawba Capital Management VA now owns 2,842 shares of the medical research company’s stock valued at $437,000 after buying an additional 435 shares during the last quarter. Institutional investors and hedge funds own 87.15% of the company’s stock.

Shares of Thermo Fisher Scientific Inc (TMO) traded up 0.87% during trading on Friday, hitting $173.23. 2,202,642 shares of the stock traded hands. The stock has a 50 day moving average price of $176.78 and a 200-day moving average price of $165.46. Thermo Fisher Scientific Inc has a 1-year low of $139.07 and a 1-year high of $182.87. The stock has a market cap of $67.58 billion, a price-to-earnings ratio of 30.18 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The business had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. During the same period in the previous year, the business posted $2.03 EPS. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. Equities analysts forecast that Thermo Fisher Scientific Inc will post $9.24 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.

WARNING: “Thermo Fisher Scientific Inc (TMO) Stake Raised by EULAV Asset Management” was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.com-unik.info/2017/08/11/eulav-asset-management-has-6-04-million-stake-in-thermo-fisher-scientific-inc-tmo-updated.html.

Several research analysts recently commented on the stock. Bank of America Corporation restated a “buy” rating and set a $210.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Barclays PLC restated an “overweight” rating and set a $200.00 target price (up previously from $190.00) on shares of Thermo Fisher Scientific in a report on Monday, July 17th. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $200.00 price target (up from $195.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 13th. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $201.00 price target (up from $182.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 10th. One investment analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $188.56.

In related news, CEO Marc N. Casper sold 20,000 shares of the business’s stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $172.79, for a total value of $3,455,800.00. Following the sale, the chief executive officer now directly owns 269,279 shares in the company, valued at approximately $46,528,718.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $176.26, for a total value of $440,650.00. Following the completion of the sale, the chief financial officer now owns 37,790 shares in the company, valued at $6,660,865.40. The disclosure for this sale can be found here. Insiders sold a total of 27,188 shares of company stock worth $4,702,223 over the last 90 days. 0.49% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit